The U.S. Food and Drug Administration has proposed a rule to modernize registration requirements for drug manufacturers that operate through centralized production networks.
According to the report, the proposal would allow companies using a "hub-and-spoke" manufacturing model to register multiple production sites as a single establishment rather than registering each facility separately.
The report said the change is intended to simplify regulatory compliance while improving oversight of pharmaceutical manufacturing.
According to the report, the proposal also strengthens registration requirements for certain foreign facilities, including manufacturers of active pharmaceutical ingredients.
The FDA said the changes would improve visibility into upstream supply chains, making it easier to trace drug products and respond to potential safety issues.
If finalized, the agency expects the rule to reduce administrative costs while increasing long-term efficiency for both regulators and the pharmaceutical industry.
Related Tweet:
US FDA proposes rule to simplify registration for some drug manufacturers https://t.co/gOqP8aVmEf https://t.co/gOqP8aVmEf
— Reuters (@Reuters) July 10, 2026
Also Read:
TIPP Staff
